Early-onset metabolic syndrome in mice lacking the intestinal uric acid transporter SLC2A9

Nature Communications

Volumn 5, Issue , 2014, Pages

  Debosch, Brian J ^a   Kluth, Oliver ^b   Fujiwara, Hideji ^a   Schürmann, Annette ^b   Moley, Kelle ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; URATE TRANSPORTER; URIC ACID; GLUCOSE TRANSPORTER; SLC2A9 PROTEIN, MOUSE; XANTHINE OXIDASE;

GENE EXPRESSION; INHIBITOR; METABOLISM; ORGANIC COMPOUND; RODENT;

ANIMAL CELL; ARTICLE; BODY FAT; DYSLIPIDEMIA; ESSENTIAL HYPERTENSION; GENETIC MODEL; GENOTYPE; GLYCOLYSIS; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERURICEMIA; HYPERURICOSURIA; IMMUNOBLOTTING; INTESTINE CELL; METABOLIC SYNDROME X; MOUSE; NONHUMAN; PHENOTYPE; PURINE METABOLISM; TRANSPORT KINETICS; URIC ACID URINE LEVEL; ANIMAL; ANTAGONISTS AND INHIBITORS; BODY COMPOSITION; C57BL MOUSE; CALORIMETRY; CHEMISTRY; ECHOCARDIOGRAPHY; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOPHYSIOLOGY;

ALLOPURINOL; ANIMALS; BODY COMPOSITION; CALORIMETRY; ECHOCARDIOGRAPHY; ENTEROCYTES; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; HYPERURICEMIA; METABOLIC SYNDROME X; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; URIC ACID; XANTHINE OXIDASE;

EID: 84907301301     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms5642     Document Type: Article

References (23)

1. Alberti, K. G. et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120, 1640 (2009).
2. Johnson, R. J. et al. Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes 62, 3307 (2013).
3. Feig, D. I., Kang, D. H. & Johnson, R. J. Uric acid and cardiovascular risk. N. Engl. J. Med. 359, 1811 (2008).
4. Nakagawa, T. et al. A causal role for uric acid in fructose-induced Metabolic Syndrome. Am. J. Physiol. Renal. Physiol. 290, F625 (2006).
5. Palmer, T. M. et al. Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts. BMJ 347, f4262 (2013).
6. Hughes, K. et al. Mendelian randomization analysis associates increased serum urate, due to genetic variation in uric acid transporters, with improved renal function. Kidney Int. 85, 344 (2014).
7. So, A. & Thorens, B. Uric acid transport and disease. J. Clin. Invest. 120, 1791 (2010).
8. Sorensen, L. B. Role of the intestinal tract in the elimination of uric acid. Arthritis Rheum. 8, 694 (1965).
9. Ichida, K. et al. Extra-renal urate excretion is a common cause of hyperuricemia. Nat. Commun. 3, 764 (2012).
10. Hosomi, A., Nakanishi, T., Fujita, T. & Tamai, I. Extra-renal elimination of uric acid via intestinal efflux transporter BCRP/ABCG2. PLoS ONE 7, e30456 (2012).
11. Anzai, N. & Endou, H. Urate transporters: an evolving field. Semin. Nephrol. 31, 400 (2011).
12. Augustin, R. et al. Identification and characterization of human glucose transporter-like protein-9 (Glut9): alternative splicing alters trafficking. J. Biol. Chem. 279, 16229 (2004).
13. Caulfield, M. J. et al. SLC2A9 is a high-capacity urate transporter in humans. PLoS Med. 5, e197 (2008).
14. Preitner, F. et al. Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy. Proc. Natl Acad. Sci.USA 106, 15501 (2009).
15. Preitner, F. et al. Urate-induced acute renal failure and chronic inflammation in liver-specific Glut9 knockout mice. Am. J. Physiol. Renal. Physiol. 305, F786 (2013).
16. Katsiki, N., Athyros, V. G., Karagiannis, A. & Mikhailidis, D. P. Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk? Curr. Vasc. Pharmacol. 9, 698 (2011).
17. Kurata, A., Shigamatsu, Y. & Hikagi, J. Sex-related differences in relations of uric acid to left ventricular hypertrophy and remodeling in Japanese hypertensive patients. Hypertens. Res. 28, 133 (2005).
18. DeBosch, B. J., Chi, M. & Moley, K. H. Glucose transporter 8 (GLUT8) regulates enterocyte fructose transport and global mammalian fructose utilization. Endocrinology 153, 4181 (2012).
19. DeBosch, B. J., Chen, Z., Finck, B. N., Chi, M. & Moley, K. H. Glucose transporter 8 (GLUT8) mediates glucose intolerance and dyslipidemia in high-fructose diet-fed male mice. Mol. Endocrinol. 27, 1887 (2013).
20. Sun, R. C., Choi, P. M., Guo, J., Erwin, C. R. & Warner, B. W. Insulin-like growth factor 2 and its enterocyte receptor are not required for adaptation in response to massive small bowel resection. J. Ped. Surg. 49, 966 (2014).
21. DeBosch, B. et al. Akt1 is required for physiological cardiac growth. Circulation 113, 2097 (2006).
22. Kim, K. M. et al. A sensitive and specific liquid chromatography-tandem mass spectrometry method for the determination of intracellular and extracellular uric acid. J. Chromatogr. B Analyst. Technol. Biomed. Life Sci. 877, 2032-2038 (2009).
23. DeBosch, B. J., Chen, Z., Saben, J. L., Finck, B. N. & Moley, K. H. Glucose transporter 8 (GLUT8) mediates fructose-induced de novo lipogenesis and macrosteatosis. J. Biol. Chem. 289, 10989 (2014).